{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:30:56Z","timestamp":1793377856239,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["5R01AI135723-03"],"award-info":[{"award-number":["5R01AI135723-03"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["T32-AI-055400"],"award-info":[{"award-number":["T32-AI-055400"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["T32 CA09171"],"award-info":[{"award-number":["T32 CA09171"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.07.029","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:26:54Z","timestamp":1784042814000},"page":"5993-6006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multivalent DNA vaccines induce potent cellular responses and prolong BCG-mediated control of Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-3499","authenticated-orcid":false,"given":"Elizabeth M.","family":"Parzych","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou A.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony N.","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne N.","family":"Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K.","family":"Duso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-3640","authenticated-orcid":false,"given":"Tricia","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shania E.","family":"Muncil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor R.F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Reiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.07.029_bib2","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","article-title":"100 years of Mycobacterium bovis bacille Calmette-Gu\u00e9rin","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR. Recomm. Rep."},{"key":"10.1016\/j.ymthe.2026.07.029_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/bmb\/ldh047","article-title":"Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, prevention and treatment","volume":"73\u201374","author":"Ormerod","year":"2005","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ymthe.2026.07.029_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087439","article-title":"Preclinical Evaluation of TB\/FLU-04L\u2014An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis","volume":"24","author":"Shurygina","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.07.029_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.07.029_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime \u2013 MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib9","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","author":"Lin","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.07.029_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36789-2","article-title":"Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults","volume":"14","author":"Sagawa","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.07.029_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","article-title":"Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection","volume":"48","author":"Lu","year":"2015","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.ymthe.2026.07.029_bib15","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib16","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib17","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2352-3018(25)00124-9","article-title":"Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E\u20134 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial","volume":"12","author":"Dagnew","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ymthe.2026.07.029_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(23)00501-7","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","volume":"24","author":"Wajja","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib19","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/infdis\/jiae170","article-title":"Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial","volume":"230","author":"Tait","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib21","doi-asserted-by":"crossref","first-page":"e0176784","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and Guinea pig TB models","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.07.029_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040166","article-title":"First-in-human trials of gamtbvac, a recombinant subunit tuberculosis vaccine candidate: Safety and immunogenicity assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.ymthe.2026.07.029_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/vaccines8040652","article-title":"Safety and immunogenicity of the gamtbvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ymthe.2026.07.029_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","article-title":"Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","volume":"12","author":"Choi","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ymthe.2026.07.029_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100163","article-title":"Optimizing antigen selection for the development of tuberculosis vaccines","volume":"3","author":"Yang","year":"2024","journal-title":"Cell Insight"},{"key":"10.1016\/j.ymthe.2026.07.029_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CMR.00042-10","article-title":"HIV and tuberculosis: a deadly human syndemic","volume":"24","author":"Kwan","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ymthe.2026.07.029_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-015-0490-8","article-title":"CD8 T cells and Mycobacterium tuberculosis infection","volume":"37","author":"Lin","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib28","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.1002212","article-title":"Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis","volume":"186","author":"Tang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","article-title":"DNA vaccines: prime time is now","volume":"65","author":"Gary","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.18609\/vac.2024.002","article-title":"Shaping immunity against infectious diseases with multivalent DNA vaccines","volume":"03","author":"Patel","year":"2024","journal-title":"Vaccin. insights"},{"key":"10.1016\/j.ymthe.2026.07.029_bib31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"nature medicine Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib32","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-Zika virus DNA vaccine \u2014 preliminary report","volume":"385","author":"Tebas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon\u00ae Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib35","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.07.029_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6\/E7 Oncogenes After Chemoradiation for Cervical Cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2026.07.029_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/oncolo\/oyad085","article-title":"Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent\/Metastatic Human Papillomavirus-Associated Cancers","volume":"28","author":"Morris","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2026.07.029_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/vaccines8010056","article-title":"Immune Therapy Targeting E6\/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis","volume":"8","author":"Aggarwal","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ymthe.2026.07.029_bib40","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/lary.30749","article-title":"Interim Results of a Phase 1\/2 Open-Label Study of INO-3107 for HPV-6 and\/or HPV-11-Associated Recurrent Respiratory Papillomatosis","volume":"133","author":"Mau","year":"2023","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ymthe.2026.07.029_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omto.2021.04.005","article-title":"A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation","volume":"21","author":"Bhojnagarwala","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.07.029_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-024-00834-y","article-title":"Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development","volume":"9","author":"Chugh","year":"2024","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0966-842X(02)02345-4","article-title":"The ESAT-6\/WXG100 superfamily - And a new Gram-positive secretion system?","volume":"10","author":"Pallen","year":"2002","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004446","article-title":"The ESAT-6 Protein of Mycobacterium tuberculosis Interacts with Beta-2-Microglobulin (\u03b22M) Affecting Antigen Presentation Function of Macrophage","volume":"10","author":"Sreejit","year":"2014","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.07.029_bib45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ni1468","article-title":"Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages","volume":"8","author":"Pathak","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib46","doi-asserted-by":"crossref","first-page":"24508","DOI":"10.1074\/jbc.M111.234062","article-title":"The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa inhibits T cell interferon-\u03b3 production through the p38 mitogen-activated protein kinase Pathway","volume":"286","author":"Peng","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.07.029_bib47","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1038\/cddis.2014.394","article-title":"Mycobacterium tuberculosis ESAT-6 is a leukocidin causing Ca2+ influx, necrosis and neutrophil extracellular trap formation","volume":"5","author":"Francis","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.mehy.2011.11.022","article-title":"The CFP10\/ESAT6 complex of Mycobacterium tuberculosis may function as a regulator of macrophage cell death at different stages of tuberculosis infection","volume":"78","author":"Guo","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ymthe.2026.07.029_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tim.2004.09.007","article-title":"ESAT-6 proteins: Protective antigens and virulence factors?","volume":"12","author":"Brodin","year":"2004","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib50","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2172-14-S1-S5","article-title":"Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e8rin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens","volume":"14","author":"Mohamud","year":"2013","journal-title":"BMC Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib51","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20041690","article-title":"Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection","volume":"200","author":"Kamath","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib52","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.4161\/hv.29574","article-title":"Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG","volume":"10","author":"Villarreal","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.07.029_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000525136","article-title":"The Effect of Delivery Systems on the Induction of T Helper 1 Cell Response to an ESAT6-Like Protein Rv3619c and Identification of Its Immunodominant Peptides","volume":"31","author":"Safar","year":"2022","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ymthe.2026.07.029_bib54","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1128\/IAI.01137-06","article-title":"Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice","volume":"75","author":"Roupie","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2026.07.029_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cimid.2018.11.016","article-title":"Rv2626c and Rv2032 activate TH1 response and downregulate regulatory T cells in peripheral blood mononuclear cells of tuberculosis patients","volume":"62","author":"Singh","year":"2019","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib56","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.micinf.2006.03.018","article-title":"Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis","volume":"8","author":"Leyten","year":"2006","journal-title":"Microbes Infect."},{"key":"10.1016\/j.ymthe.2026.07.029_bib57","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1016\/j.vaccine.2009.04.033","article-title":"Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime\/protein boost vaccination regimen in mice","volume":"27","author":"Bivas-Benita","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib58","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/CVI.00271-15","article-title":"Synthetic long peptide derived from mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis","volume":"22","author":"Coppola","year":"2015","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1128\/CVI.00111-09","article-title":"Immunogenicity of novel DosR regulon-encoded candidate antigens of mycobacterium tuberculosis in three high-burden populations in Africa","volume":"16","author":"Black","year":"2009","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib60","article-title":"In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination","volume":"6","author":"Coppola","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.micinf.2011.08.011","article-title":"Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines","volume":"14","author":"Romano","year":"2012","journal-title":"Microbes Infect."},{"key":"10.1016\/j.ymthe.2026.07.029_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7774\/cevr.2014.3.2.235","article-title":"DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8(+) T cell responses","volume":"3","author":"Lee","year":"2014","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"10.1016\/j.ymthe.2026.07.029_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196815","article-title":"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis","volume":"13","author":"Leung-Theung-Long","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.07.029_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41541-023-00666-2","article-title":"A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG","volume":"8","author":"Dijkman","year":"2023","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.00140009","article-title":"Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection","volume":"36","author":"Goletti","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2026.07.029_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109238","article-title":"Mycobacterium tuberculosis dormancy regulon proteins Rv2627c and Rv2628 as Toll-like receptor agonist and as potential adjuvant","volume":"112","author":"Bhatt","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib67","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.1201593","article-title":"An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection","volume":"190","author":"Commandeur","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib68","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2014.05.005","article-title":"The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs","volume":"32","author":"Commandeur","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib69","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.chom.2015.10.008","article-title":"M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens","volume":"18","author":"Coscolla","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2026.07.029_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1609136","article-title":"A review of the efficacy of clinical tuberculosis vaccine candidates in mouse models","volume":"16","author":"del Pozo-Ramos","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.029_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1586\/14760584.2015.990890","article-title":"Electroporation-enhanced delivery of nucleic acid vaccines","volume":"14","author":"Broderick","year":"2015","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib72","series-title":"Methods in Microbiology S. Kaufmann","author":"Roberts","year":"2002"},{"key":"10.1016\/j.ymthe.2026.07.029_bib73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1586\/14760584.2014.929947","article-title":"Human type 5 adenovirus-based tuberculosis vaccine: Is the respiratory route of delivery the future?","volume":"13","author":"Smaill","year":"2014","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2026.07.029_bib74","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ymthe.2026.07.029_bib75","doi-asserted-by":"crossref","first-page":"e0175215","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. journals.plos.orgCF von Reyn, T Lahey","volume":"12","author":"Von Reyn","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.07.029_bib76","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1080\/21645515.2017.1335374","article-title":"Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis","volume":"13","author":"Huang","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.07.029_bib77","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI\u00ae","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.07.029_bib78","article-title":"Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.07.029_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00728-20","article-title":"Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from plasmodium infection in a murine model","volume":"89","author":"Reeder","year":"2021","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2026.07.029_bib80","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-20-0061","article-title":"A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control","volume":"8","author":"Xu","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.07.029_bib81","doi-asserted-by":"crossref","first-page":"e00242-21","DOI":"10.1128\/mBio.00242-21","article-title":"Synthetic dna delivery of an optimized and engineered monoclonal antibody provides rapid and prolonged protection against experimental gonococcal infection","volume":"12","author":"Parzych","year":"2021","journal-title":"MBio"},{"key":"10.1016\/j.ymthe.2026.07.029_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh4379","article-title":"Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers","volume":"9","author":"Bordoloi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.07.029_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008733","article-title":"Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.07.029_bib84","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.07.029_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies (DMAb) in healthy adults: a phase 1 trial","author":"Tebas","year":"2025","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:33:04Z","timestamp":1793374384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626005976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525001626005976"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.029","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent DNA vaccines induce potent cellular responses and prolong BCG-mediated control of Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}